Use of 2MD, a Novel Oral Calcitriol Analog, in Hemodialysis Patients with Secondary Hyperparathyroidism.

CONCLUSIONS: In hemodialysis patients with SHPT, 2MD, at thrice weekly oral doses of 440 and 550 ng, is well tolerated and effectively suppresses PTH without hypercalcemia. Future studies are needed to study the long-term implications of treating ESRD patients with this novel VDRA. PMID: 27096733 [PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/27096733?dopt=Abstract

Source: American Journal of Nephrology - April 20, 2016 Category: Urology & Nephrology Authors: Pandey R, Zella J, Clagett-Dame M, Plum LA, DeLuca HF, Coyne DW Tags: Am J Nephrol Source Type: research